NewLink’s HyperAcute Program In Limbo After Pancreatic Trial Blow-Up
Company says it is evaluating what to do with its HyperAcute vaccine candidates in various tumor types, as focus shifts toward IDO programs.
Company says it is evaluating what to do with its HyperAcute vaccine candidates in various tumor types, as focus shifts toward IDO programs.